The BCLC Classification System
The Barcelona Clinic Liver Cancer (BCLC) classification is a comprehensive staging system for hepatocellular carcinoma (HCC) that divides patients into 5 stages (0, A, B, C, and D) based on tumor burden, liver function, and performance status, while simultaneously linking each stage to specific evidence-based treatment recommendations 1.
Why BCLC is the Preferred Staging System
The BCLC classification is endorsed by major international guidelines including EASL, EORTC, and AASLD 1, 2, 3. It is the only staging system that both predicts prognosis AND assigns treatment allocation to specific prognostic subclasses 1. Unlike other systems (CLIP, CUPI, JIS), BCLC uniquely integrates:
- Tumor status: size, number, vascular invasion, extrahepatic spread
- Liver function: Child-Pugh classification
- Performance status: ECOG score
- Treatment-dependent variables: bilirubin, portal hypertension, symptoms 1
The system has been extensively validated across different clinical settings and populations 1, 3.
The Five BCLC Stages
Stage 0 (Very Early)
- Single tumor <2 cm
- Child-Pugh A
- ECOG 0
- Treatment: Resection, radiofrequency ablation, or liver transplantation
- Expected survival: >60 months median 1, 4
Stage A (Early)
- Single tumor OR up to 3 nodules ≤3 cm
- Child-Pugh A-B
- ECOG 0
- Treatment: Resection, liver transplantation, or radiofrequency ablation
- Expected survival: >60 months median, 40-70% 5-year survival 1, 4
Stage B (Intermediate)
- Multinodular disease beyond Milan criteria
- No vascular invasion or extrahepatic spread
- Child-Pugh A-B
- ECOG 0
- Treatment: Transarterial chemoembolization (TACE)
- Expected survival: ~20 months median 1, 4
Stage C (Advanced)
- Portal vein invasion OR extrahepatic metastases
- Child-Pugh A-B
- ECOG 1-2
- Treatment: Systemic therapy (atezolizumab + bevacizumab, or sorafenib)
- Expected survival: ~11 months median 1, 4
Stage D (Terminal)
Evolution and Updates
The BCLC system is dynamic and evolves with new evidence 1. Originally introduced in 1999, it was updated in 2003 to incorporate Stage 0 and TACE for intermediate HCC, then modified in 2008 to add sorafenib for advanced disease 1. The 2025 update incorporates atezolizumab + bevacizumab as first-line treatment for advanced stages 5.
Critical Limitations in Real-World Practice
A major caveat: approximately 30% of HCC patients cannot receive BCLC-recommended first-line treatment in clinical practice 6, 7. Common reasons include:
- Technical limitations (74% of deviations) 7
- Patient refusal (20%) 7
- Disease progression during workup 7
Stages B and C are particularly heterogeneous, containing diverse patient populations with varying tumor burdens and liver function 8, 9. This has led to calls for substaging within these categories, especially for patients with portal vein thrombosis where treatment outcomes differ dramatically based on extent (subsegmental vs. segmental vs. main trunk) 8.
Geographic Variations
While BCLC is the standard in Western countries, Asian guidelines often expand surgical indications beyond BCLC recommendations, particularly for Stage B and selected Stage C patients 4. Studies show that carefully selected patients outside strict BCLC criteria may still benefit from surgical resection 10, 11.
The key strength of BCLC remains its ability to provide both prognostic stratification and treatment guidance in a single, validated framework that can be applied across diverse clinical settings 1, 3.